Attached files

file filename
EX-10.1 - WOUND MANAGEMENT TECHNOLOGIES, INC.wmti8kex101010913.htm


 
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549


FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported): January 2, 2013

 
Wound Management Technologies, Inc.
(Exact name of registrant as specified in its charter)

Texas
0-11808
59-2219994
(State or other jurisdiction
(Commission File
(IRS Employer
incorporation)
Number)
Identification No.)



777 Main Street, Suite 3100, Fort Worth, Texas  76102
    (Address of principal executive offices)    (Zip Code)



Registrant’s telephone number, including area code   817-820-7080 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[_]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)

[_]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

[_]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))
 
 
 
 
 
 

 
 
Item 1.01Entry into a Material Definitive Agreement

As disclosed in the Quarterly Report on Form 10-Q filed by Wound Management Technologies, Inc. (the “Company”) for the three months ended September 30, 2012, on August 17, 2012, Tonaquint, Inc. (“Tonaquint”)  and the Company entered into a forbearance agreement with respect to that certain Secured Convertible Promissory Note in the original principal amount of $560,000 (the “Note”), pursuant to which Tonaquint agreed, among other things, to refrain from exercising its rights under the Note through October 16, 2012, subject to two optional 30-day extension periods. On December 5, 2012, Tonaquint and the Company entered into a First Amendment to Forbearance Agreement, adding a third optional 30-day extension period.

On January 2, 2013, Tonaquint and the Company entered into a Second Amendment to Forbearance Agreement, adding a fourth optional 30-day extension period.


Item 9.01.  Financial Statements and Exhibits

(d)           Exhibits

10.1                      Second Amendment to Forbearance Agreement dated January 2, 2013
 
 
 
 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
WOUND MANAGEMENT TECHNOLOGIES, INC.
   
Date:  January 9, 2013
 
 
By:   /s/  Robert Lutz, Jr.                                           
 
Robert Lutz, Jr., Chief Executive Officer